Table 1.
Cohort data on patients with VA ≥ 1.3 logMAR
| All diseases | AMD | DME | RVO | P | |
|---|---|---|---|---|---|
| Number of patients (N) | 164 | 107 | 15 | 42 | |
|
Age at first injection Median in years (range) |
78 (30–94) |
80 (51–94) |
67 (30–84) |
76 (33–93) |
< 0.0001 |
|
Gender: female/male N (%) |
87/77 (53.0/47.0) |
57/50 (53.3/46.7) |
7/8 (46.7/53.3) |
23/19 (54.8/45.2) |
0.913 |
| Eye: right/left (%) |
77/87 (47.0/53.0) |
49/58 (45.8/54.2) |
8/7 (53.3/46.7) |
20/22 (52.4/47.6) |
0.886 |
|
Number of injections within time periods after initial IVI Median (range) | |||||
| 0 to 6 months | 5 (2–7) | 5 (3–7) | 6 (2–7) | 5 (3–7) | 0.341 |
| 6 to 12 months | 3 (0–7) | 3 (0–6) | 2 (0–4) | 3 (1–7) | 0.006 |
| 12 to 18 months | 2 (0–6) | 2 (0–6) | 0 (0–4) | 2 (0–5) | 0.075 |
| 18 to 24 months | 0 (0–5) | 0 (0–5) | 0 (0–5) | 0 (0–5) | 0.614 |
The values in bold are statistically significant. There was a significant age difference between patients with AMD, DME and RVO. In addition, there was a significant difference in the number of injections between patients with DME, AMD, and RVO in the 2nd half of the year